Skip to content
Screener

Viridian Therapeutics, Inc. VRDN Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$75.0K
EPS-$1.00In line
EPS estimate-$1.00

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$4.0M
EPS estimate-$0.99

Financials

Q2 2025

Income statement

See full
Revenue$75.0K+4.2%
Operating income-$106.8M-47.9%
Net income-$100.7M-55.0%

Balance sheet

See full
Cash & equivalents$117.3M+9.0%
Total debt$23.1M+2.1%
Total equity$515.2M-2.7%
Total assets$582.3M-0.6%

Cash flow

See full
Operating cash flow-$75.4M-63.6%
CapEx$42.0K-59.6%
Free cash flow-$75.4M-63.4%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$1.2B+44.1%
Enterprise value$1.1B+47.9%
P/S3,921.8×+1,039×

Profitability

See full
Operating margin-121,831.1%+80,915pp
Net margin-112,806.9%+83,238pp
FCF margin-101,507.9%+276,805pp

Returns & leverage

See full
Return on equity-65.9%+18.7pp
Debt / equity0×0.0×
Current ratio11×-4.8×

FAQ

When did Viridian Therapeutics, Inc. report Q2 2025 earnings?
Viridian Therapeutics, Inc. (VRDN) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Viridian Therapeutics, Inc.'s Q2 2025 revenue and EPS?
Viridian Therapeutics, Inc. reported revenue of $75.0K and eps of $-1.00 for Q2 2025.
Did Viridian Therapeutics, Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-1.00 by $0.00.
How did Viridian Therapeutics, Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 4.2% from $72.0K a year earlier and eps grew 2.0% from $-1.02.
Where can I find Viridian Therapeutics, Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-173983) and the 10-Q periodic report (0001590750-25-000012) directly on SEC EDGAR. The filing index links above go to sec.gov.